drugset / Trial / NCT07140510

Dinalbuphine Sebacate in Postoperative Pain Control After TKA

NCT07140510

Phase 4 Not yet recruiting 100 enrolled Thammasat University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the effectiveness of Dinalbuphine Sebacate for controlling subacute pain after total knee arthroplasty

Timeline

Start
2025-10
Primary completion
2026-06
Completion
2026-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Dinalbuphine sebacate Small molecule 150 mg Intramuscular

Indications